Discover investment opportunities in Best Biotech Stocks For 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Biotech Stocks For 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Biotech Stocks For 2024 using our Smart AI Filter.
9 stocks found for "Best Biotech Stocks For 2024"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.70 | ±46.8% | 1.5 | 0.00% | |||
0.34 | ±25.2% | 8.0 | 0.00% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.63 | ±35.0% | 27.1 | 0.00% | |||
0.83 | ±70.5% | -3.5 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.22 | ±27.3% | 15.0 | 2.83% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does Regeneron Pharmaceuticals (REGN) position itself in the biotech industry?
A: Regeneron Pharmaceuticals is known for its innovative monoclonal antibody drugs. It has strong R&D capabilities and partnerships, contributing to its robust pipeline. Recent successes with EYLEA and Dupixent demonstrate its potential, though investors should watch for competitive pressures and patent expirations.
Q: What growth prospects does Vertex Pharmaceuticals (VRTX) have in rare diseases?
A: Vertex Pharmaceuticals focuses on cystic fibrosis treatments, with Trikafta being a significant revenue driver. Investors view its pipeline expansion into other rare diseases as promising, though the success of these developments remains uncertain and should be closely monitored.
Q: Why might Amgen (AMGN) appeal to dividend-focused investors?
A: Some investors consider Amgen for its stability and reliable dividend payments, with a history of consistent increases. However, it faces pressure to innovate as biosimilars threaten its established product portfolio.
Q: Is Gilead Sciences (GILD) positioned well for long-term growth in antiviral drugs?
A: Gilead Sciences has a strong presence in antiviral therapies, including HIV and Hepatitis C, and is expanding into oncology. Investors should monitor competitive developments and patent challenges that may impact its future revenue streams.
Q: What challenges does Biogen (BIIB) face in the Alzheimer’s treatment space?
A: Biogen's Alzheimer's therapies, such as Aduhelm, face regulatory scrutiny and uncertain efficacy outcomes. While there is high market potential, approval hurdles and competition from other treatments are key risks to consider.
Q: How does Illumina (ILMN) contribute to advances in genomic sequencing?
A: Illumina is a leader in genomic sequencing, integral to advances in precision medicine. Its technologies are widely used in research and clinical settings, though patent disputes and reliance on innovation present ongoing risks.